Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
USWM, LLC (dba US WorldMeds)
Eli Lilly and Company
Eli Lilly and Company
Hoffmann-La Roche
Bayer
National Cancer Institute (NCI)
Turning Point Therapeutics, Inc.
Ipsen
Novartis
Deciphera Pharmaceuticals, LLC
Blueprint Medicines Corporation